AV
Alexandria Venture Investments
Pasadena, California, United StatesFounded 1996
Alexandria Venture Investments focuses on early- to growth-stage companies across life science, agriculture, technology, and sustainability sectors. Their strategy involves making strategic investments and leveraging their parent company's extensive ecosystem to foster innovation and growth within their portfolio.
Portfolio
29
Fund Size
$1.6B
Top Stage
Series A
Last 12 Mo
7
Stage Distribution
Portfolio
29 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Precede Biosciences | Series B | $63.5M | Jan 2026 |
| Recludix Pharma | Unknown | — | Jan 2026 |
| Tr1X, Inc. | Series C | $50M | Oct 2025 |
| Crystalys Therapeutics Inc. | Series A | $205M | Sep 2025 |
| Leal Therapeutics, Inc. | Series A | $30M | Aug 2025 |
| Hoofprint Biome | Series A | $15M | Apr 2025 |
| Solu Therapeutics | Series A | $41M | Apr 2025 |
| Autoimmunity BioSolutions | Seed | $2M | Nov 2024 |
| Axonis Therapeutics | Series A | $115M | Oct 2024 |
| Archon Bioscience | Seed | $20M | Oct 2024 |
| March Biosciences | Series A | $28.4M | Oct 2024 |
| Ability Biologics | Seed | $18M | Jun 2024 |
| Elo Life Systems | Series A | $20.5M | Jan 2024 |
| Tr1X, Inc. | Series A | $75M | Jan 2024 |
| Aspen Neuroscience | Series B | $147.5M | May 2022 |
| Pheast Therapeutics | Series A | $76M | Apr 2022 |
| Creyon Bio | Seed | $40M | Mar 2022 |
| Meiogenix | Series A | $13M | Dec 2021 |
| Deka Biosciences | Series A | $20M | Nov 2021 |
| Disc Medicine | Series B | $90M | Sep 2021 |
| LQT Therapeutics, Inc. | Series A | $19M | Aug 2021 |
| Mnemo Therapeutics | Series A | $90M | Jun 2021 |
| Senda Biosciences | Series B | $55M | Jun 2021 |
| Invaio Sciences | Series C | $88.9M | May 2021 |
| Soteria Biotherapeutics | Series A | $42M | May 2021 |
Page 1 of 2
Top Co-Investors
OrbiMed5 shared
ARCH Venture Partners4 shared
DCVC Bio3 shared
Novo Holdings3 shared
The Column Group3 shared
Casdin Capital3 shared
Sofinnova Partners3 shared
Mirae Asset2 shared
Atlas Venture2 shared
Access Biotechnology2 shared
Flagship Pioneering2 shared
Eli Lilly and Company2 shared
AccelR81 shared
Catalio Capital Management1 shared
GV (Google Ventures)1 shared
LYFE Capital1 shared
Revelation Partners1 shared
EDBI1 shared
Lifeforce Capital1 shared
Frazier Life Sciences1 shared
Last updated: 1 March 2026